Semaglutide and Tirzepatide Linked to Reduced Skin Cancer Risk in Obese Patients

Real-world data directly comparing the safety and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. Beyond their metabolic effects, Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated anti-inflammatory and wound-healing properties. While their impact on outcomes after dermatologic surgery has been explored, their potential influence on skin cancer risk, particularly melanoma and nonmelanoma types, has not been fully evaluated. This study addresses a critical gap in understanding the broader dermatological safety and potential benefits of these widely used agents.

This was a nationwide multicenter observational study that compared outcomes in obese patients treated with semaglutide and tirzepatide. The primary objective was to assess the risk of developing melanoma and nonmelanoma skin cancers in these patient cohorts. The study design focused on real-world data, observing patient outcomes over time. Specific details regarding patient numbers, exact dosing protocols, treatment duration, or the nature of the control groups were not provided in the abstract.